Preprint · OA
via OpenAlex
α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease
Ilaria Guella, Daniel M. Evans, Chelsea Szu‐Tu, Ekaterina Nosova, Stephanie Bortnick, SNCA Cognition Study Group, Jennifer G. Goldman, John C. Dalrymple‐Alford, Gert J. Geurtsen, Irene Litvan, Owen A. Ross, Lefkos T. Middleton, Laura Parkkinen, Matthew James Farrer
Annals of Neurology · 2016 · ▲ 94 citations
Abstract
OBJECTIVE: The relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitively intact in the long term. Alpha-synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia. In worldwide populations, SNCA genetic variability remains the most reproducible risk factor for idiopathic PD. However, few investigators have looked at SNCA variability in terms of cognitive outcomes. METHODS: We have used targeted high-throughput sequencing to characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB and healthy controls. RESULTS: An analysis of 43 tagging single nucleotide polymorphisms across the SNCA locus shows 2 distinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3' or the 5' of the SNCA gene. In addition, we define a specific haplotype in intron 4 that is directly associated with PDD. The PDD risk haplotype has been interrogated at single nucleotide resolution and is uniquely tagged by an expanded TTTCn repeat. INTERPRETATION: Our data show that PD, PDD, and DLB, rather than a disease continuum, have distinct genetic etiologies albeit within one genomic locus. Such results may serve as prognostic biomarkers to these disorders, to inform physicians and patients, and to assist in the design and stratification of clinical trials aimed at disease modification. Ann Neurol 2016;79:991-999.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/ana.24664
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Guella, I., Evans, D.M., Szu‐Tu, C., Nosova, E., Bortnick, S., Group, S.C.S., Goldman, J.G., Dalrymple‐Alford, J.C., Geurtsen, G.J., Litvan, I., Ross, O.A., Middleton, L.T., Parkkinen, L., & Farrer, M.J. (2016). α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease. <em>Annals of Neurology</em>. https://doi.org/10.1002/ana.24664
Vancouver
Guella I, Evans DM, Szu‐Tu C, Nosova E, Bortnick S, Group SCS, et al. α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease. Annals of Neurology. 2016. doi:10.1002/ana.24664.
BibTeX
@unpublished{ilaria2016synucl,
title = {α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease},
author = {Ilaria Guella and Daniel M. Evans and Chelsea Szu‐Tu and Ekaterina Nosova and Stephanie Bortnick and SNCA Cognition Study Group and Jennifer G. Goldman and John C. Dalrymple‐Alford and Gert J. Geurtsen and Irene Litvan and Owen A. Ross and Lefkos T. Middleton and Laura Parkkinen and Matthew James Farrer},
journal = {Annals of Neurology},
year = {2016},
doi = {10.1002/ana.24664},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Trends in Genetics 2018
Open access · CC-BY
Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics
Journal of Hypertension 2002
Citation only
Arterial stiffness and prediction of cardiovascular risk
Frontiers in aging neuroscience 2026
Citation only
Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.
iScience 2023
Open access · CC-BY
Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson’s disease
Movement Disorders 2016
Preprint · OA
Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression
Journal of Neurochemistry 2019
Open access · CC-BY